The European Medicines Agency's Committee for Medicinal Products for Human Use recommended against approving Pfizer's rheumatoid arthritis drug Xeljanz, or tofacitinib. The drug improved patients' physical function and RA symptoms but it failed to sufficiently demonstrate "a consistent reduction in disease activity and structural damage to joints," the committee said. Pfizer plans to appeal the recommendation.
Pfizer's RA drug Xeljanz fails to win EU panel support
SmartBrief Job Listings for Health Care
|Sr. Medical Device Reimbursement Specialist - Regional||
|Fort Worth , TX|
|Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group||
|Clinical Trials Agreements Specialist (209955)||
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
|SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST||
Matheson Tri-Gas, Inc.
ASAHI INTECC, Orange County CA R&D Center
|Santa Ana, CA|